BP016W-新型食道鱗狀上皮細胞癌候選藥物

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：154

、訪客IP：3.149.251.26

姓名

賴家祥(Chia-Hsiang Lai) 查詢紙本館藏

畢業系所

系統生物與生物資訊研究所

論文名稱

BP016W-新型食道鱗狀上皮細胞癌候選藥物
(BP016W- as a Novel Candidate Drug for Esophageal squamous Cell Carcinoma Therapy)

相關論文

★ 中草藥BP004誘導管腔A型乳腺癌細胞凋亡	★ 藉由微陣列基因晶片以探討中草藥BP011w對於抑制肺腺癌細胞株爬行及轉移之機制
★ 鑑別可應用在病理與臨床之肺腺癌與鱗狀上皮細胞肺癌的生物標記	★ 中國傳統醫藥蒙古黃耆在HCT116結腸癌細胞體外和體內實驗呈現腫瘤抑制作用
★ 泰莫西芬與BP012W乙醇分離物之協同作用造成強化管狀A型乳腺癌細胞凋亡影響	★ 揭示CEP55基因在大腸直腸癌轉移中所扮演的角色
★ 傳統中藥複方FY001W是三陰性乳腺癌新型的候選藥物	★ BP023W在頭頸癌中的細胞毒性與調控機制
★ 藉由L1000?表達圖譜數據來解釋中醫分類方法中的屬性和歸經	★ Solasodine，BP010W成份之一，抑制肺癌的遷移和侵襲能力
★ 蒙古黃耆對大腸癌影響並降低miR-29a的表現量之研究	★ 利用生物資訊策略找出普濟方內加速傷口癒合的新配方
★ 藉助模塊化網路策略尋找普濟方之治療疾病核心配方	★ 探索 BP010W 的治療潛力:基於雌激素信號通路, 以澳洲茄胺作為抑製劑研究肺癌細胞遷移的綜合分析
★ 大數據分析糖尿病患者使用糖尿病藥物後得病因果關係和風險比較以桃園某地區醫院為例

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

[檢視]

[下載]

本電子論文使用權限為同意立即開放。
已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中)

食道鱗狀上皮細胞癌是一個致命的癌症，它有高死亡率及嚴重的化療副作用。因此，我們決定找出新的食道癌治療藥物。我們首先分析食道鱗狀上皮細胞癌患者之轉錄子定序及基因微陣列晶片資料，並從中篩選了727個轉錄子(363上調轉錄子及364下調轉錄子)。接著，使用基因分析工具及藥物預測工具發現到它們的結果與降血脂藥物相關。近年來許多文獻以及臨床研究顯示天然藥物可以用於治療癌症，它有著低毒性並且可以抗發炎及抑制癌症細胞的生長。於是，我們搜尋有關降血脂的天然藥物並且從實驗中看到BP016W可以抑制癌細胞的生長。我們利用流式細胞儀看到BP016W抑制癌細胞的方式是促使癌細胞走向程序性凋亡路徑，接著我們使用西方墨點法證明細胞程序性凋亡蛋白被啟動。為了探討更全面的基因路徑表現以及蛋白質體學代謝表現，我們使用轉錄子次世代定序與蛋白質質譜儀來觀察癌細胞治療前後基因及蛋白質表現量差異。從高通量數據我們發現BP016W治療癌細胞可以抑制脂肪代謝及細胞生長路徑，這樣的結果表示我們之前的預測方法是正確的。從過去的文獻指出抑制脂肪代謝可以促使細胞走向程序性凋亡。所以，我們認為BP016W可以當作新的食道癌治療後選藥物。

摘要(英)

Esophageal squamous cell carcinoma (ESCC) is one of the most common lethal tumors in the world. It has low cure rate and has serious side effects of chemotherapy. We analyzed 15 patients’ transcriptome sequencing and microarray data selecting 727 transcripts (363 up- and 364 down-regulated) significant to the ESCC, finally. Then we put these signatures into LINCScloud database and the results indicated that hypolipidemic related drugs might be a novel approach for ESCC therapy. Traditional Chinese medicines (TCMs) originated in ancient China and has evolved over thousands of years. Many previous studies have indicated these bioactive natural products can inhibit the interaction, promotion, and progression of carcinogenesis in human cancer cells, and have low toxicity. So, the old book about the TCM was found that there were 4 herbs which related to our prediction. In the study, we screened 4 TCMs and found that BP016W, one of the families of Nelumbo, shows strong growth inhibition toward the ESCC cell line CE81T, thus was chosen for further study. Our western blotting and flow cytometry data both confirmed the term of apoptosis. The protein mass and transcriptome sequencing data also showed that the cholesterol was inhibited and could affect the mitochondria to cause the cell to be apoptosis. Eventually, we think that BP016W is a novel candidate for ESCC therapy.

關鍵字(中)

★ 食道鱗狀上皮細胞癌
★ 天然藥物
★ 轉錄子定序
★ 蛋白質質譜
★ 生物資訊
★ 降血脂藥物
★ 細胞程序性凋

關鍵字(英)

★ Esophageal squamous cell carcinoma
★ Traditional Chinese Medicine
★ Transcriptome sequencing
★ Protein mass
★ Bioinformatics
★ Hypolipidemic drug
★ Apoptosis

論文目次

Table of contents

中文摘要……………………………………………………………………………………......i
Abstract……………………………………………………………………………………...…ii
誌謝………………………………………………………………………………………...…iii
Table of Contents…………………………………………………………………………...…iv
List of Figures…………………………………………………………………………………vi
List of Tables…………………………………………………………………………………viii
List of Supplements Figures………………………………………………………………...…ix
List of Supplements Tables……………………………..…………………………………........x
1. Introduction………………………………………………………………………………….1
2. Materials and Method……………………………………………………………………….3
2-1. Cell culture………………………………………………………………………………...3
2-2. Preparation of Folium Nelumbinis……………………………………………………...…3
2-3. Preparation of Lovastatin………………………………………………………………….3
2-4. Cell viability assay………………………………………………………………………...4
2-5. Apoptosis and cell cycle analysis…………………………………………………………4
2-6. Preparation of protein extract……………………………………………………………..5
2-7. Western blotting…………………………………………………………………………...5
2-8. Preparation of RNA extract……………………………………………………………….6
2-9. Data analysis………………………………………………………………………………6
2-10. HPLC analysis of different fractions…………………………………………………….6
3. Result………………………………………………………………………………………..8
3-1. Bioinformatic analysis…………………………………………………………………….8
3-1-1. Transcriptome sequencing & functional analysis………………………………………8
3-1-2. Microarray analysis of Taiwanese ESCC patients…………………………………….13
3-2. Lovastatin caused ESCC’s cell line to be apoptosis……………………………………..15
3-2-1. In vitro cytotoxicity study by Alamar blue assay……………………………………...15
3-2-2. Analysis of apoptosis by cell cytometry……………………………………………….17
3-2-3. Expression of apoptotic pathway proteins by western blot……………………………18
3-2-4. Transcriptome sequencing analysis of CE81T treated with lovastatin………………..19
3-3. Hypolipidemic drug in Traditional Chinese medicine…………………………………...21
3-4. Folium Nelumbinis (BP016W) caused ESCC’s cell line to be apoptosis………………..23
3-4-1. BP016W suppressed ESCC’s cell line growth...............................................................23
3-4-2. Western blot verified pathway of apoptosis…………………………………………...25
3-4-3. Transcriptome sequencing analysis of CE81T treated with BP016W………………...27
3-4-4. Protein mass analysis of CE81T treated with BP016W……………………………….29
3-5. Active compound of fraction from BP016W…………………………………………….32
3-5-1. The isolated method of BP016W……………………………………………………...32
3-5-2. HPLC analysis…………………………………………………………………………35
4. Discussion………………………………………………………………………………….37
5. Reference…………………………………………………………………………………..42
6. Supplements………………………………………………………………………………..44

參考文獻

1. 衛生福利部. 民國105年主要死因分析. 2017; Available from: https://www.mohw.gov.tw/cp-16-33598-1.html.
2. TORRE, Lindsey A., et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians, 2015, 65.2: 87-108.
3. SHERMAN, Brad T., et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols, 2009, 4.1: 44-57.
4. EDGAR, Ron; DOMRACHEV, Michael; LASH, Alex E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research, 2002, 30.1: 207-210.
5. DOMON, Bruno; AEBERSOLD, Ruedi. Mass spectrometry and protein analysis. science, 2006, 312.5771: 212-217.
6. ASHBURNER, Michael, et al. Gene Ontology: tool for the unification of biology. Nature genetics, 2000, 25.1: 25-29.
7. LIU, Chenglin, et al. Compound signature detection on LINCS L1000 big data. Molecular BioSystems, 2015, 11.3: 714-722.
8. HUANG, Chunfa; FRETER, Carl. Lipid metabolism, apoptosis and cancer therapy. International journal of molecular sciences, 2015, 16.1: 924-949.
9. THIBAULT, Alain, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clinical Cancer Research, 1996, 2.3: 483-491.
10. SINGH, Siddharth, et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett′s esophagus: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology, 2013, 11.6: 620-629.
11. LI-WEBER, Min. Targeting apoptosis pathways in cancer by Chinese medicine. Cancer letters, 2013, 332.2: 304-312.
12. FU, Junjie, et al. Discovery of gene regulation pattern in lung cancer by gene expression profiling using human tissues. Genomics data, 2015, 3: 112-115.
13. KIM, Hyun-Joong, et al. Microarray detection of food-borne pathogens using specific probes prepared by comparative genomics. Biosensors and Bioelectronics, 2008, 24.2: 238-246.
14. TRAPNELL, Cole, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature protocols, 2012, 7.3: 562-578.
15. COX, Jurgen, et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. Journal of proteome research, 2011, 10.4: 1794-1805.
16. LEONE, Gemma, et al. Development of liposomal formulations to potentiate natural lovastatin inhibitory activity towards 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase. Journal of Drug Delivery Science and Technology, 2018, 43: 107-112.
17. ELF, Shannon E.; CHEN, Jing. Targeting glucose metabolism in patients with cancer. Cancer, 2014, 120.6: 774-780.
18. DESCHNER, Eleaner; LIPKIN, Martin. Proliferation and differentiation of gastrointestinal cells in relation to therapy. Medical Clinics of North America, 1971, 55.3: 601-612.
19. KOVACEVIC, Zaklina; RICHARDSON, Des R. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis, 2006, 27.12: 2355-2366.
20. ANDO, Takuya, et al. Decreased expression of NDRG1 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Diseases of the Esophagus, 2006, 19.6: 454-458.
21. HUNTER, Michael, et al. NDRG1 interacts with APO AI and A-II and is a functional candidate for the HDL-C QTL on 8q24. Biochemical and biophysical research communications, 2005, 332.4: 982-992.
22. COLELL, Anna, et al. Cholesterol impairs the adenine nucleotide translocator-mediated mitochondrial permeability transition through altered membrane fluidity. Journal of Biological Chemistry, 2003, 278.36: 33928-33935.

指導教授

蘇立仁

審核日期

2018-1-23

推文